Anyone who is under 45 years of age and a high cholesterol level has, suffers later in life more likely to have a heart attack or a stroke than older people, with bad values. The largest study shows to this question, which is now in the journal "The Lancet" appeared.
That high cholesterol the risk for cardiovascular disease increase, is well researched. The extent to which age plays a role, has studied an international group of researchers now, on the basis of data from nearly 400,000 people. The participants were at the beginning of the observation period, on average, 51 years old, and were accompanied on average 13.5 years. At the beginning of the study, once your so-called non-HDL cholesterol in the blood. These physicians include all Cholesterol types other than rated as good, HDL cholesterol.
As the authors Dr. Fabian Brunner and Dr. Christoph Waldeyer, from the University heart and vascular center, UKE Hamburg reports that it came during this period to a total of 54,500 cardiovascular events. The amount of cholesterol was linked directly with age and cardiovascular risk: This was the higher, the younger the participants were, with elevated non-HDL-cholesterol levels.
For example, the probability of suffering up to the age of 75 years, a heart attack or stroke; in people under 45 years of age with a non-HDL value between 3.7 and 4.8 mmol/l and two additional cardiovascular risk factors for women is 16 and for men, 29 percent. In the case of people aged 60 and over with the same characteristics, the probabilities were, however, only 12 and 21 percent. If patients below 45 years of age, to halve your non-HDL value, would decrease the risk for women to 4 per cent, and for men to 6 per cent, calculated by the authors.
Long-term use of statins have not been explored yet
Such a strong reduction in non-HDL cholesterol, however, is reached only with a long-term drug therapy, said Professor Dr. Jennifer Robinson of the University of Iowa. That would mean, as a rule, the years of taking so-called statins. The safety of this cholesterol-lowering drug has been in studies for a maximum of seven years studied – and not over decades. The potential Benefit of such a long treatment should be, therefore, set in relation to their potential damage due to adverse drug reactions. This needs to be examined from the point of view of the researcher before recommendations are made.
DOI 10.1016/S0140-6736(19)32519-X DOI 10.1016/S0140-6736(19)32949-6
An Overview of all the messages you get on aponet.de current.